Table 1 Overall AP regulatory activity evaluated by hemolysis and an ELISA-based method: Best fit IC50 calculated by 4PL nonlinear regression model.
From: A synthetic protein as efficient multitarget regulator against complement over-activation
Assay | MFHR13 | MFHR1I62 | MFHR1V62 | hFH | Eculizumab |
|---|---|---|---|---|---|
AP ELISA | |||||
IC50 (nM) | 17.8 | 19.3 | 33.1 | 665 | 38.2 |
95% CI | 16.9–18.9 | 16.1–22.5 | 29.4–37.4 | 477.2–893.3 | 34–42.9 |
R2 | 0.99 | 0.95 | 0.95 | 0.78 | 0.96 |
Hemolysis | |||||
IC50 (nM) | 4.9 | 14.3 | 18.4 | 21.3 | 128.8 |
95% CI | 3.7–7.2 | 10.8–21.7 | 14.3–27.2 | 14.8–37.0 | 115.5–152.6 |
R2 | 0.96 | 0.89 | 0.96 | 0.98 | 0.70 |
